Clinical Trial Update: Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

View source ↗

Summary

An observational study evaluating lutetium-177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium-177 Vipivotide Tetraxetan (lutetium-177 vipivotide tetraxetan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Castration Resistant Prostate Cancer | Status: RECRUITING